Cutaneous adverse events in children treated with vemurafenib for refractory BRAF V600E mutated Langerhans cell histiocytosis-Reference-Cited by-同舟云学术

Cutaneous adverse events in children treated with vemurafenib for refractory BRAF V600E mutated Langerhans cell histiocytosis

Published:2021-06-09 Issue:9 Volume:68 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Tardieu Mathilde¹^ORCID,Néron Amélie²,Duvert‐Lehembre Sophie³,Amine Larabi Islam⁴,Barkaoui Mohamed⁵,Emile Jean‐Francois⁶,Seigneurin Arnaud⁷,Boralevi Franck⁸,Donadieu Jean⁵^ORCID

Affiliation:

1. Pediatric Dermatology Department Grenoble Alpes University Hospital Grenoble France

2. Dermatology Department Grenoble Alpes University Hospital Grenoble France

3. Dermatology Department Lille University Hospital Lille France

4. Department of Pharmacology and Toxicology Paris‐Saclay University (Versailles Saint‐Quentin‐en‐Yvelines University), Inserm U‐1173, Raymond Poincaré Hospital Garches France

5. French Reference Center for Langerhans Cell Histiocytosis Trousseau Hospital Paris France

6. Pathology Department & EA4340‐BECCOH Ambroise Paré Hospital, AP‐HP & Versailles SQY University Boulogne France

7. TIMC‐IMAG Laboratory Grenoble Alpes University, Grenoble Alpes University Hospital Grenoble France

8. Pediatric Dermatology Unit Hôpital Pellegrin‐Enfants Bordeaux France

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29140

Reference55 articles.

1. Langerhans-Cell Histiocytosis